HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Michael Weller Selected Research

Procarbazine (Matulane)

7/2020How did lomustine become standard of care in recurrent glioblastoma?
1/2020Calculating the net clinical benefit in neuro-oncology clinical trials using two methods: quality-adjusted survival effect sizes and joint modeling.
10/2016The Role of Molecular Diagnostics in the Management of Patients with Gliomas.
12/2014The management of lomustine overdose in malignant glioma patients.
12/2013Anaplastic oligodendroglioma: a new treatment paradigm and current controversies.
9/2012Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q testing for malignant glioma patients in clinical practice.
9/2011NOA-05 phase 2 trial of procarbazine and lomustine therapy in gliomatosis cerebri.
12/2009NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
1/2008Procarbazine and CCNU as initial treatment in gliomatosis cerebri.
4/2003Radiochemotherapy of malignant glioma in adults. Clinical experiences.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Michael Weller Research Topics

Disease

255Neoplasms (Cancer)
12/2022 - 01/2002
234Glioblastoma (Glioblastoma Multiforme)
12/2022 - 01/2002
213Glioma (Gliomas)
08/2022 - 01/2002
46Brain Neoplasms (Brain Tumor)
01/2022 - 05/2002
28Astrocytoma (Pilocytic Astrocytoma)
01/2022 - 05/2002
20Neoplasm Metastasis (Metastasis)
10/2022 - 06/2003
19Lymphoma (Lymphomas)
08/2021 - 02/2002
17Oligodendroglioma
01/2022 - 10/2002
16Meningioma (Meningiomas)
01/2022 - 01/2016
14Hypoxia (Hypoxemia)
09/2015 - 08/2002
12Melanoma (Melanoma, Malignant)
01/2022 - 08/2002
11Multiple Sclerosis
01/2019 - 10/2003
10Necrosis
04/2021 - 05/2003
9Disease Progression
01/2022 - 09/2002
9Seizures (Absence Seizure)
11/2021 - 08/2005
9Infections
01/2021 - 01/2003
9Epilepsy (Aura)
01/2020 - 01/2006
7Stroke (Strokes)
10/2021 - 12/2009
6Thrombocytopenia (Thrombopenia)
01/2022 - 10/2002
6Breast Neoplasms (Breast Cancer)
01/2020 - 12/2002
5Fatigue
01/2022 - 07/2015
5Central Nervous System Neoplasms
01/2022 - 10/2007
5Edema (Dropsy)
10/2021 - 12/2010
5Inflammation (Inflammations)
12/2017 - 11/2003
4Lymphopenia (Lymphocytopenia)
01/2022 - 12/2010
4Lung Neoplasms (Lung Cancer)
01/2021 - 11/2013
4Medulloblastoma
05/2020 - 03/2002

Drug/Important Bio-Agent (IBA)

89Temozolomide (Temodar)FDA LinkGeneric
11/2022 - 03/2002
64Proteins (Proteins, Gene)FDA Link
11/2022 - 01/2002
43Biomarkers (Surrogate Marker)IBA
03/2022 - 12/2007
43Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA
01/2022 - 10/2009
37Bevacizumab (Avastin)FDA Link
01/2022 - 04/2010
34DNA (Deoxyribonucleic Acid)IBA
01/2022 - 02/2006
32Pharmaceutical PreparationsIBA
01/2022 - 08/2002
31Messenger RNA (mRNA)IBA
10/2021 - 05/2002
29LigandsIBA
10/2021 - 01/2002
24MethyltransferasesIBA
01/2021 - 02/2006
24Alkylating AgentsIBA
03/2020 - 03/2005
23Lomustine (CCNU)FDA Link
08/2021 - 05/2002
22CytokinesIBA
03/2022 - 10/2003
21ErbB Receptors (EGF Receptor)IBA
10/2021 - 01/2002
20Transforming Growth Factors (Transforming Growth Factor)IBA
01/2022 - 10/2004
20Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
06/2021 - 08/2002
19Biological ProductsIBA
03/2022 - 11/2003
17Transforming Growth Factor beta (TGF-beta)IBA
12/2016 - 10/2004
15IntegrinsIBA
05/2018 - 12/2009
14CaspasesIBA
04/2020 - 03/2002
14CilengitideIBA
05/2018 - 12/2009
12AntigensIBA
01/2021 - 05/2003
12Vincristine (Oncovin)FDA LinkGeneric
07/2020 - 09/2002
12O(6)-Methylguanine-DNA MethyltransferaseIBA
07/2014 - 09/2008
11Immune Checkpoint InhibitorsIBA
11/2022 - 08/2015
11Phosphotransferases (Kinase)IBA
01/2022 - 11/2004
11O-(6)-methylguanineIBA
01/2021 - 02/2006
11Procarbazine (Matulane)FDA Link
07/2020 - 10/2002
10AntibodiesIBA
03/2019 - 01/2002
9Anticonvulsants (Antiepileptic Drugs)IBA
11/2021 - 08/2005
9Death Domain ReceptorsIBA
09/2013 - 01/2002
8Adrenal Cortex Hormones (Corticosteroids)IBA
03/2021 - 12/2010
8Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
10/2020 - 05/2002
8MicroRNAs (MicroRNA)IBA
01/2020 - 08/2011
8EnzymesIBA
01/2016 - 05/2005
7epidermal growth factor receptor VIIIIBA
12/2022 - 12/2012
7Angiogenesis InhibitorsIBA
01/2022 - 09/2010
7Neutralizing AntibodiesIBA
12/2019 - 11/2003
6SteroidsIBA
10/2021 - 12/2010
6Peptides (Polypeptides)IBA
01/2021 - 08/2002
6InterferonsIBA
04/2020 - 09/2012
6Small Interfering RNA (siRNA)IBA
10/2017 - 10/2004
6Methotrexate (Mexate)FDA LinkGeneric
09/2017 - 02/2002
6Fas Ligand Protein (Fas Ligand)IBA
09/2013 - 01/2002
6HLA-G Antigens (HLA G)IBA
11/2005 - 05/2002
5Fibronectins (Fibronectin)IBA
03/2022 - 01/2013
5RNA (Ribonucleic Acid)IBA
01/2022 - 10/2006
5VaccinesIBA
01/2021 - 01/2004
5Telomerase (Telomerase Reverse Transcriptase)IBA
01/2021 - 12/2013
5Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
11/2020 - 01/2016
5Amino AcidsFDA Link
11/2020 - 01/2003
5Protein Isoforms (Isoforms)IBA
01/2018 - 11/2013
5AcidsIBA
06/2016 - 01/2005
5Intercellular Signaling Peptides and Proteins (Growth Factors)IBA
01/2016 - 05/2013
5CeramidesIBA
01/2013 - 09/2007
4NivolumabIBA
11/2022 - 01/2017
4depatuxizumab mafodotinIBA
08/2021 - 01/2020
4NF-kappa B (NF-kB)IBA
06/2021 - 01/2007
4Cyclin-Dependent Kinases (cdk Proteins)IBA
12/2020 - 12/2009
4EpitopesIBA
10/2020 - 01/2018
4Irinotecan (Camptosar)FDA LinkGeneric
03/2020 - 02/2006
4Phosphatidylinositols (Phosphatidylinositol)IBA
01/2020 - 03/2004
4Glucose (Dextrose)FDA LinkGeneric
01/2020 - 03/2005
4Monoclonal AntibodiesIBA
01/2020 - 10/2013
4TOR Serine-Threonine KinasesIBA
01/2020 - 03/2004

Therapy/Procedure

130Therapeutics
11/2022 - 01/2002
105Radiotherapy
11/2022 - 01/2002
104Drug Therapy (Chemotherapy)
08/2022 - 09/2002
39Immunotherapy
03/2022 - 12/2003
33Chemoradiotherapy
11/2022 - 04/2003
6Aftercare (After-Treatment)
10/2022 - 01/2012
5Palliative Care (Palliative Therapy)
12/2020 - 09/2013
5Precision Medicine
10/2019 - 01/2010